9:56 AM · 3 October 2023

Novo Nordisk gains after FDA and US patent office decision

Europe's largest listed company, Novo Nordisk (NOVOB.DK) is gaining nearly 2% in today's session following decisions by the FDA and the US patent office. A tribunal of the U.S. patent office rejected a request by Mylan Pharmaceuticals to review the validity of patents held by Novo on the main active ingredients in Wegova and Ozempic. What's more, the FDA, or U.S. Food and Drug Administration, has approved Novo Nordisk's making a proprietary therapy to treat a rare genetic defect of the kidneys. 

The drug will be given by injection under the brand name Rivfloza. The therapy is to be priced according to the clinical value and benefit of people struggling with the disease, the company added. There may be more than 2,000 such individuals (suffering from hyperoxaluria) in the US, the company added. 

Source: xStation 5

8 September 2026, 12:58 PM

ASML is picking up pace again.

8 September 2026, 11:37 AM

Novartis shares fall the most since 2020 📉 What is behind the 10% decline?

7 September 2026, 1:58 PM

Market Wrap: Far-right AfD wins in Germany, oil continues to rise (07.09.2026)

7 September 2026, 8:59 AM

Economic Calendar: ECB decision, Oracle results, and US inflation - what to expect? (07.09.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits